AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00604318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rhTSH
Description: The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
Study NCT00604318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhTSH
Description: The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
Study NCT04469387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited decompressions at adjacent segment with asymptomatic pre-existing spinal canal stenosis
Description: In terms of limited decompression at the adjacent segment, partial laminotomy, flavectomy, and bilateral medial facetectomies up to the pedicle will be performed. Complete laminectomy and destroy of posterior ligament complex will be avoided.
Study NCT04469387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Responsible segments fused
Description: In terms of responsible segments fused, L4-5 and L5-S1 were fused using posterior lumbar interbody fusion (PLIF).
Study NCT04469387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Responsible segments fused
Description: In terms of responsible segments fused, L4-5 and L5-S1 were fused using posterior lumbar interbody fusion (PLIF).
Study NCT03958864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001
Study NCT01555034 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: movement therapy
Description: exercise, nutrition, movement therapy
Study NCT01555034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise plus nutrition
Description: exercise, nutrition
Study NCT02483351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Red Blood Cell Transfusion Strategy
Description: Optional RBC Transfusion with hemoglobin trigger of \<=80g/L
Study NCT04602299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Set the minimum time of gastroscopy
Description: This study contains 2 stages. At the first stage, no interventions are implemented. The researchers just observe the actual procedure time of gastroscopy. At the second stage, a minimal procedure time is set based on the observational results of the first stage.
Study NCT04584645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted digital intervention
Description: Messages that provide informational content on the influenza vaccine (sourced from the Centers for Disease Control and Prevention and the American Heart Association), specific information about influenza and cardiovascular disorders, and behavioral prompts (e.g., reminders) surrounding influenza vaccination behaviors.
Study NCT01654536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclesonide nasal aerosol
Description: ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol)
Study NCT01654536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclesonide nasal spray
Description: ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray)
Study NCT02554448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ISET system
Description: Use ISET system to test the number of CTCs from patients before and during treatment.
Study NCT00276744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Study NCT00276744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Study NCT00276744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Study NCT00276744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Study NCT00276744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Study NCT00276744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Study NCT04239066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tourniquet
Description: tubularized incided plate (TIP) urethroplasty plus tourniquet
Study NCT04239066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-tourniquet
Description: tubularized incided plate (TIP) urethroplasty plus non-tourniquet
Study NCT00276744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Study NCT00276744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Study NCT00276744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Study NCT02171520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate generation I
Study NCT02171520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate generation II
Study NCT02771912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol and excipients
Study NCT02771912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Qualitative composition of Propofol lipuro 2% excipients
Study NCT01462097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: 12 months of aerobic exercise
Study NCT01462097 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: 12 months of health education sessions
Study NCT02364752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Study NCT02364752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop Diuretic Withdrawal/Salt Load
Study NCT03260673 — intervention group
Intervention type: OTHER
Intervention: specular microscope
Description: The corneal endothelial cell density, variation in endothelial cell size (CV), percentage of hexagonal cells, and central corneal thickness(CCT) were recorded at baseline and at 3 months postoperatively.
Study NCT03371303 — intervention group
Intervention type: OTHER
Intervention: collection of prescription data
Description: collection of prescription data before and after a hospitalization
Study NCT00906828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: intestinal gel, continuous infusion (daytime or 24-hour)
Study NCT00906828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entacapone
Description: Tablet, 200 mg, given twice during the study at t=0h and t=5hrs
Study NCT00906828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolcapone
Description: Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
Study NCT03061227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous glucagon
Description: Randomized application of glucagon or saline during oral glucose tolerance test
Study NCT03061227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous saline
Description: Randomized application of glucagon or saline during oral glucose tolerance test
Study NCT03099512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SFE
Description: The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
Study NCT03099512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercises which improves muscle strength, ROM...
Study NCT03099512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercises which improves muscle strength, ROM...
Study NCT01564485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Description: A cardiac CT involves a non-invasive test of the coronary arteries.
Study NCT01564485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual medical care
Description: Patients would be treated by their primary care physicians with usual medical care with drugs such as lipid lowering medication, blood pressure lowering medications, and blood glucose lowering medications. The study will not specify which drugs to use and will it up to the individual physician's discretion.
Study NCT01975727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of placebo (saline 0.9%)
Study NCT03793270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: for patients and healthy donors
Description: 1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry~2. Determine the serum level of IL 10 using ELISA plate
Study NCT01975727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 3 mg
Description: 10 ml Seringue with Dexamethasone
Study NCT04576273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pathology examination
Description: Gross and microscopic evaluation
Study NCT03695120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change of treatment plan
Description: Withholding ACEI/ARBs during initial 72 hours of admission with acute decompensated heart failure may help preserve renal function with a lesser decline in GFR. This treatment modification will also allow the option of aggressive diuresis in volume overloaded CHF patients which should result in a lesser decline of AKI, length of stay, readmission rates, and cost associated with CHF treatment.
Study NCT00824239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent sedation
Description: Patients under intermittent sedation stay without any continuous sedation since intubation and/or admission but receive analgesics as needed and sedatives only when agitated (SAS of 5 or more).
Study NCT00824239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Daily interruption of sedation
Description: Patients under daily interruption of sedation stay on continuous sedation with midazolam and fentanyl and are submitted to a daily interruption of sedation to a neurological evaluation until they reach a SAS of 4 or more, then continuous sedation is re-started in the half previous dosage.
Study NCT02205632 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MPS II
Study NCT03921671 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed and / or metastatic, in the first line.
Study NCT06175910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous nephrolithotomy
Description: A 7 Fr ureteric catheter was placed into the ipsilateral ureteric orifice. The patients were then placed in the prone position. Opacification of the pelvicalyceal system was performed. The puncture was done by a 22-guage puncture needle was advanced into the posterior lower calyx under fluoroscopic guidance. After successful access is established, a 0.035-inch curved guide wire was advanced through the puncture needle into the kidney. The central Alkane Rod was passed over the guide wire. Under fluoroscopic guidance serial Amplatz dilators up to 30 Fr were advanced over central Alkane rod and guide wire. Then 30 Fr long Amplatz sheath was advanced over the last dilator.~26 Fr rigid long nephroscope used for stone fragmentation and retrieval. Stone fragmentation was done by pneumatic Swiss Lithoclast. Fragments removal was done using toothed peanut stone retrieval forceps.
Study NCT06175910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retrograde intrarenal surgery
Description: urethrocystoscopy was carried out then inserting of a 7F open ended ureteral catheter over the 0.035-inch straight floppy tip guide wire in the working channel of the 22Fr cystoscope under fluoroscopic guidance, access to the ureter was made.~Teflon ureteric dilators are used to dilate the distal ureter till 14 FR. ureteral access sheath placement 12 or 14 Fr. OTU, a disposable digital flexible ureteroscope, is then used then the tip of a 272 m holmium laser fiber is placed on the surface of the stone for fragmentation.~Intra renal lithotripsy was carried out using a 30 W Holmium: YAG laser (Sphinx Jr.) via a 272 m silica quartz laser fiber. 1.9 Fr tipless nitinol baskets were finally used to remove the large fragments. A Double-J (6 Fr) stent is generally applied at the end of the procedure, and a urethral catheter was applied.
Study NCT01008488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Antibiotic according to local treatment routine against bowel pathogenesis
Study NCT03438344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-antigen CMV-Modified Vaccinia Ankara Vaccine
Description: Given IM
Study NCT03438344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03438344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03438344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IM
Study NCT02984709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention
Description: Health Behavior Contract - Baseline visit Education Packet - Baseline visit Positive psychology training for teen and parents - baseline visit Parent praise reminder (text message) - one time per week (over 8 week intervention period) Teen gratitude message (text message) - every Monday (over 8 week intervention period) Teen positive value message (text message) - every Wednesday (over 8 week intervention period) Teen mood booster (text message) - every Thursday and Saturday and alternative Sundays (over 8 week intervention period) Small gift ($5 gift card code sent every 2 weeks for 8 weeks)
Study NCT02984709 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Health Behavior Contract - Baseline visit Education Packet - Baseline visit
Study NCT05221515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anger can go!
Description: The intervention Anger Can Go! was designed to treat anger regulation problems in autistic children aged 8 to 13 years old. The intervention consists of nine sessions of 60 minutes and is divided in four phases. Phase 1: psycho-education, affect-education and measuring anger with an anger-thermometer. This is a self-report scale presented as the drawing of a thermometer, that allows the child to indicate his level of anger, as linked to specific bodily and behavioral representations on a scale from 0 to 3. Phase 2: making a functional behavior assessment (FBA) and taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts. Phase 3: taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts, shifting attention away from aversive stimuli, to cope with the stress of the anger provoking situation. Phase 4: creating solutions to cope with an anger provoking situation.
Study NCT05221515 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent psycho-education
Description: Three psycho-educational parent group sessions (take place before the children's sessions in intervention group). Parents meet with other parents and a therapist to learn about the nature of their Expressed Emotion (EE) and how it relates to the child's aggressive behavior.
Study NCT05221515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent psycho-education
Description: Three psycho-educational parent group sessions (take place before the children's sessions in intervention group). Parents meet with other parents and a therapist to learn about the nature of their Expressed Emotion (EE) and how it relates to the child's aggressive behavior.
Study NCT04938804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography
Description: The Low-dose computed tomography is conducted according to the guideline suggested by American College of Radiology.
Study NCT01932112 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adenosine arm
Description: After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
Study NCT03565926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: 1. Articulation technique L4-S1~2. Lumbar neuromuscular technique~3. Fascial technique of crossed hands~4. Posteroanterior mobilizations of the lumbar vertebrae
Study NCT03565926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive exercises
Description: Protocol 5 Hypopressive exercises
Study NCT00865358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Group
Description: Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
Study NCT00118924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LGT(TP21)/DEN4
Description: Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)
Study NCT00118924 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for LGT(TP21)/DEN4 vaccine
Study NCT02559115 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-RM2 (RM2)
Study NCT01540526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: 7 mg PO BID days 1-14 in 21 day cycles.
Study NCT02048644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostair
Description: beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
Study NCT02048644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matched inhaler 2puffs to be taken twice a day for 28 days
Study NCT02052661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B Kinder
Description: Single dose administered intramuscularly in deltoid region of non-dominant arm.
Study NCT00420082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Encapsulated Bilastine 20 mg tablets Q.D.
Study NCT00420082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Encapsulated Fexofenadine 120 mg tablets Q.D.
Study NCT00420082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: Encapsulated Cetirizine 10 mg tablets Q.D.
Study NCT00420082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated Placebo tablets Q.D.
Study NCT04548570 — intervention group
Intervention type: PROCEDURE
Intervention: approximation of both rectus muscles
Description: closure of both rectus muscle before closure of rectus sheeth
Study NCT01975727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 6 mg
Description: 10 ml Seringue with Dexamethasone
Study NCT01975727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 12 mg
Description: 10 ml Seringue with Dexamethasone